Condition: Pneumocystis Pneumonia · Sponsor: Mundipharma Research Limited
This study aims to generate clinical data on the efficacy, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole for treatment of Pneumocystis pneumonia (PCP) in adults living with human immunodeficiency virus (HIV), which would expand the knowledge of clinical use of rezafungin.
This description comes directly from the study's public registry record.
Elizabeth Chong, MSc · +441223424900 · Clinicaltrialsinfo@mundipharma-rd.eu
Terry Nichols · Clinicaltrialsinfo@mundipharma-rd.eu
Always discuss trial participation with your own doctor first.
| University of Cape Town | Cape Town, South Africa | Recruiting |
| Charlotte Maxeke Johannesburg Academic Hospital | Johannesburg, South Africa | Recruiting |
| Helen Joseph Hospital | Johannesburg, South Africa | Terminated |
| Global Clinical Trials - Pretoria | Pretoria, South Africa | Recruiting |
| Steve Biko Academic Hospital | Pretoria, South Africa | Recruiting |
| Netcare Umhlanga Medical Centre | Umhlanga, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05835479